Lupin receives tentative approval from USFDA for generic Tadalafil Tablets

19 Jul 2018 Evaluate

Lupin has received tentative approval for its Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Eli Lilly and company's Cialis Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg.

It is indicated for the treatment of erectile dysfunction, the signs and symptoms of benign prostatic hyperplasia and erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia. Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg had annual sales of approximately $1949.2 million in the US (IQVIA MAT April 2018).

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2176.25 -18.75 (-0.85%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×